KELOWNA, BC / ACCESSWIRE / May 8, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that dosing of the targeted 36 subjects in its human clinical oral nicotine study NIC-H22-1 has been completed. Human study NIC-H22-1 represents the culmination of… Read More..

Results Confirm and Extend Response Results from Phase 3 FLASH Study PRINCETON, N.J., May 4, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today positive… Read More..

SKYX website portfolio now spans 64 websites for lighting and home décor products - including most leading U.S. lighting brands Acquisition expected to accelerate SKYX's go-to-market for its plug and play safe and smart ceiling platform products with retail and professional segments including builders, architects and designers MIAMI FL /… Read More..